A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

This study looks at how well a new treatment, called idecabtagene vicleucel (or ide-cel), works compared to a standard treatment, lenalidomide (LEN), for adults with a blood cancer called Multiple Myeloma. Multiple Myeloma is a disease where harmful cells grow in the bone marrow. After a special treatment that uses their own stem cells, some people still don't get the best response. This study will see if adding ide-cel to LEN can help these people better than just using LEN alone.

Participants must be 18 or older, have been newly diagnosed with Multiple Myeloma, and have had specific treatments before joining. They also must not have certain other health conditions.

• Study involves two different treatments to compare effectiveness.
• Participants must have had previous treatments and meet specific health criteria.
• Safety and side effects of the new treatment will be closely monitored.

Being part of a clinical study can help doctors learn more about new treatments and might offer participants the chance to try a new therapy that could be beneficial. 😊